New drug combo aims to tame blood vessel inflammation

NCT ID NCT06957002

Not yet recruiting Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial tests whether adding bosentan to standard steroid treatment helps people with giant cell arteritis (GCA) avoid relapses and reduce steroid use. About 40 adults with GCA will receive either bosentan plus steroids or steroids alone for 3 months, then be followed for a year. The goal is to see if the combination leads to better outcomes with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bosentan (a drug that helps blood vessels relax) and glucocorticoids (steroids)
What this could lead to: If it works, this could offer a way to reduce relapses and lower the need for long-term steroids in people with giant cell arteritis.
What could go wrong: This is a small, early-phase trial with only 40 participants. The drug may not prove better than steroids alone, and bosentan can have side effects like liver problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS (GCA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIANT CELL ARTERITIS (GCA)

Contacts and locations

Locations

Unité de Recherche Clinique, Entrepôts de données et Pharmacologie GHU Paris Centre

Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.